The first MRD data from the phase 3 EXCALIBER-RRMM trial support iberdomide-based triplet therapy as early as first relapse, with PFS follow-up ongoing.
|Videos|June 30, 2017
Dr. Ross on the Treatment of Liver Metastasis in Melanoma
Author(s)Merrick I. Ross, MD
Merrick I. Ross, MD, professor, Department of Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, discusses treatment for liver metastasis in patients with melanoma.
Advertisement
Merrick I. Ross, MD, professor, Department of Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, discusses treatment for liver metastasis in patients with melanoma.
Liver metastasis is a very difficult problem for a variety of reasons, explains Ross. It’s possible that the active immunotherapy agents may not be as effective in the liver.
Of the patients who have metastatic disease, 95% of them will have some component of liver metastasis, states Ross.
<<<
Advertisement
Related to this article
After nearly 7 years of follow-up, daratumumab added to VRd continued to improve PFS, PFS2, and sustained MRD negativity in transplant-eligible myeloma.
Monthly etentamig significantly improved response and PFS over standard available therapies in the phase 3 CERVINO trial, with low rates of high-grade CRS.
Extended follow-up from the phase 1b CAMMA 1 trial showed durable responses across two cevostamab dose levels, supporting selection of a recommended phase 3 regimen.
A MAIC found anito-cel produced response rates similar to those of cilta-cel, with fewer high-grade toxicities, in relapsed/refractory multiple myeloma.
Updated phase 2 LINKER-SMM1 data show single-agent, fixed-duration linvoseltamab produced deep, durable, and MRD-negative responses in high-risk smoldering multiple myeloma.
Shailender Bhatia, MD, discusses next steps for adjuvant therapy research in light of the phase 3 ADAM trial data and broader implications for Merkel cell carcinoma.
Shailender Bhatia, MD, discusses ADAM trial design, key efficacy and safety findings, and treatment implications in Merkel cell carcinoma.
Advertisement
Advertisement
Trending on OncLive
1
Ifinatamab Deruxtecan BLA Voluntarily Withdrawn in Previously Treated Extensive-Stage SCLC
2
Etentamig Improves Response and PFS vs Standard Therapies in Triple-Class Exposed Relapsed/Refractory Myeloma
3
Dr Voorhees on Eligibility Criteria for the CERVINO Trial in Multiple Myeloma
4
Long-Term PERSEUS Data Confirm Durable PFS Benefit With D-VRd in Transplant-Eligible Newly Diagnosed Myeloma
5